Related Experiment Video
Updated: Feb 4, 2026

Using High Content Imaging to Quantify Target Engagement in Adherent Cells
Published on: November 29, 2018
Use of a Web-Based Shared Decision-Making Program: Impact on Ongoing Treatment Engagement and Antipsychotic Adherence
Molly T Finnerty1, Deborah M Layman1, Qingxian Chen1
1Dr. Finnerty, Ms. Layman, Ms. Chen, Dr. Leckman-Westin, and Ms. Bermeo are with the New York State Office of Mental Health (NYSOMH), New York. Dr. Finnerty is also with the Department of Child and Adolescent Psychiatry, New York University Langone Health, New York, where Dr. Hoagwood is affiliated. Ms. Layman is also a doctoral student, Department of Psychology, Fordham University, New York. Dr. Leckman-Westin is also with the Department of Epidemiology and Biostatistics, School of Public Health, State University of New York at Albany, Rensselaer, New York. Dr. Ng-Mak is with Sunovion Pharmaceuticals, Inc., Marlborough, Massachusetts, and Dr. Rajagopalan is with Sunovion Pharmaceuticals, Inc., Fort Lee, New Jersey.
Objective:
The authors examined the impact of a Web-based shared decision-making application, MyCHOIS-CommonGround, on ongoing outpatient mental health treatment engagement (all users) and antipsychotic medication adherence (users with schizophrenia).
Methods:
An intervention study was conducted by comparing Medicaid-enrolled MyCHOIS-CommonGround users in 12 participating mental health clinics (N=472) with propensity score-matched adults receiving services in nonparticipating clinics (N=944). Medicaid claims were used to assess ongoing treatment engagement and antipsychotic adherence (among individuals with schizophrenia) one year prior to and after entry into the cohort. Multilevel linear models were conducted to estimate the effects of the MyCHOIS-CommonGround program over time.
Results:
No differences during the baseline year were found between the MyCHOIS-CommonGround group and the matched control group on demographic, diagnostic, or service use characteristics. At one-year follow-up, engagement in outpatient mental health services was significantly higher for MyCHOIS-CommonGround users than for the control group (months with a service, 8.54±.22 versus 6.95±.15; β=1.40, p<.001). Among individuals with schizophrenia, antipsychotic medication adherence was also higher during the follow-up year among MyCHOIS-CommonGround users compared with the control group (proportion of days covered by medication, .78±.04 versus .69±.03; β=.06, p<.01).
Conclusions:
These findings provide new evidence that shared decision-making tools may promote ongoing mental health treatment engagement for individuals with serious mental illness and improved antipsychotic medication adherence for those with schizophrenia.
Related Concept Videos
Decision Making
Automatic decision-making is fast, intuitive, and relies on gut feelings...
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Impact of Groups on Groups
Decision Making: P-value Method
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can...
Antipsychotic Drugs: Typical and Atypical Agents

